Predictive value of PSA density in the diagnosis of prostate cancer in lebanese men
https://doi.org/10.4081/aiua.2022.1.18
Accepted: October 15, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Objective: Being the second most common cancer in men, prostate cancer detection relies on laboratory tests, imaging, and surgical procedures, although biopsy remains the mainstay in diagnosis of prostate cancer. No clear cut-off of prostate specific antigen density (PSAD) for suspecting prostate cancer has been established in the Lebanese population. Our primary objective was to evaluate the diagnostic strength of the PSAD value versus total prostate specific antigen (tPSA) level in the Lebanese men in correlation with biopsy outcome to avoid unnecessary prostate biopsy.
Methods: A retrospective study of 347 patients with history of prostate biopsy done for cancer suspicion included tPSA, prostate volume, and prostate density values and results of prostate biopsy. Data was collected from Bahman hospital and statistical analysis of the mean values of tPSA, prostate volume and PSAD in different age groups was done. Significance of the results was tested using.
Results: On average, patients with negative biopsies were younger and they had lower tPSA levels, lower PSAD values and larger prostate volume compared to patients with positive biopsies. A PSAD cutoff of 0.185 ng/ml2 revealed the highest predictive strength for prostate cancer (6 times risk) compared with other parameters. These findings were mainly referred to patients with PSA > 10 ng/ml.
Conclusions: A multifactorial approach must be conducted including all parameters in order to decide upon the need for prostate biopsy. PSAD proved to be a good marker in favor or against a prostate biopsy with a cut-off of 0.185 ng/ml2, especially in patients with tPSA level higher to 10 ng/ml. A multicenter study was recommended for better and more reliable results and more precise cut-offs.
Rogers OC, Anthony L, Rosen DM, et al. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 2018; 9:22436-22450. DOI: https://doi.org/10.18632/oncotarget.25091
Prcic A, Begic E, Hiros M. Usefulness of total PSA value in prostate diseases diagnosis. Acta Inform Med. 2016; 24:156-61. DOI: https://doi.org/10.5455/aim.2016.24.156-161
Mittal RD. Reference range of serum prostate-specific antigen levels in Indian men. Indian J Med Res. 2014; 140:480-1. PMID:25488440; PMCID: PMC4277132.
Shamseddine A, et al. Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018.Popul Health Metr. 2014; 12:4. DOI: https://doi.org/10.1186/1478-7954-12-4
https://gco.iarc.fr/today/data/factsheets/populations/422-lebanonfact-sheets.pdf
Instituto Brasileiro de Geografia e Estatística; Ministério do Planejamento, Orçamento e Gestão. Estimativas populacionais 1980-2010: Brasil, regiões geográficas e unidades da federação. Rio de Janeiro (Brasil): IBGE; 2010. [citado em 15 de junho de 2010]. Disponível em: http://www.ibge.gov.br
Nickel JC. Inflammation and benign prostatic hyperplasia. Urol
Clin North Am. 2008; 35:109-15 DOI: https://doi.org/10.1016/j.ucl.2007.09.012
Çamur E, Coskun A, Kavukoglu O, et al. Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients. Arch Ital Urol Androl. 2019; 91:93. DOI: https://doi.org/10.4081/aiua.2019.2.93
Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal. 1990; 4:135-7. DOI: https://doi.org/10.1002/jcla.1860040212
Bell N, et al. Canadian Task Force on Preventive Health Care.Recommendations on screening for prostate cancer with the prostatespecific antigen test. CMAJ. 2014; 186:1225-34. DOI: https://doi.org/10.1503/cmaj.140703
Park HK, Hong SK, Byun SS, Lee SE. Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0 ng/mL and the patients with a serum PSA level in the range 4.1 to 10.0 ng/mL. Korean J Urol. 2006; 47:358-61. DOI: https://doi.org/10.4111/kju.2006.47.4.358
Kobayashi T, Nishizawa K, Ogura K, et al. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population. Urology. 2004; 63:727-31. DOI: https://doi.org/10.1016/j.urology.2003.11.025
Gomes R, Rebello LEFS, Araújo FC, et al. A prevenção do câncer de próstata: uma revisão da literatura. Ciencia & Saude Coletiva. 2008; 13:235-46. DOI: https://doi.org/10.1590/S1413-81232008000100027
Benson MC, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147:815-6. DOI: https://doi.org/10.1016/S0022-5347(17)37393-7
Jue JS, et al. Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy. Urology. 2017; 105:123-128. DOI: https://doi.org/10.1016/j.urology.2017.04.015
Stephan C, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005; 104:993-1003. DOI: https://doi.org/10.1002/cncr.21267
Van Iersel MP, Witjes WP, de la Rosette JJ, Oosterhof GO. Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. Br J Urol. 1995; 76:47-53. DOI: https://doi.org/10.1111/j.1464-410X.1995.tb07586.x
Ediz C, Akan S, Temel MC, Yilmaz O. The importance of PSA Density in active surveillance for prostate cancer. Arch Ital Urol Androl. 2020; 92:136. DOI: https://doi.org/10.4081/aiua.2020.2.136
Holmäng S, Lindstedt G, Mårin P, Hedelin H. Serum concentration of prostate-specific antigen in relation to prostate volume in 50 healthy middle-aged men. Scand J Urol Nephrol. 1993; 27:15-20. DOI: https://doi.org/10.3109/00365599309180408
Catalona WJ, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000; 56:255-60. DOI: https://doi.org/10.1016/S0090-4295(00)00637-3
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
